专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08124779B2 Process for the preparation of esomeprazole non-salt form 失效
标题翻译：制备艾美拉唑非盐形式的方法
公开(公告)号：US08124779B2
公开(公告)日：2012-02-28
申请号：US12096199
申请日：2006-12-04
申请人： Martin Bohlin , Per Lindberg
发明人： Martin Bohlin , Per Lindberg
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： The present invention relates to a new process for the preparation of new crystal modifications of esomeprazole non-salt form. Further, the present invention also relates to the use of said new crystal modifications for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as the crystal modifications, as such.
摘要翻译：本发明涉及用于制备艾美拉唑非盐形式的新晶体修饰的新方法。此外，本发明还涉及所述新的晶体修饰物用于治疗胃肠道疾病，含有它们的药物组合物以及晶体修饰物的用途。

2. 发明申请

US20080269297A1 Process for the Preparation of Esomeprazole Non-Salt Form 失效
标题翻译：艾美拉唑非盐形式的制备方法
公开(公告)号：US20080269297A1
公开(公告)日：2008-10-30
申请号：US12096199
申请日：2006-12-04
申请人： Martin Bohlin , Per Lindberg
发明人： Martin Bohlin , Per Lindberg
IPC分类号： A61K31/4439 , C07D401/12
CPC分类号： C07D401/12
摘要： The present invention relates to a new process for the preparation of new crystal modifications of esomeprazole non-salt form. Further, the present invention also relates to the use of said new crystal modifications for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as the crystal modifications, as such.
摘要翻译：本发明涉及用于制备艾美拉唑非盐形式的新晶体修饰的新方法。此外，本发明还涉及所述新的晶体修饰物用于治疗胃肠道疾病，含有它们的药物组合物以及晶体修饰物的用途。

3. 发明授权

US5877192A Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole 失效
标题翻译：使用奥美拉唑（ - ）对映异构体治疗胃酸相关疾病和生产药物的方法
公开(公告)号：US5877192A
公开(公告)日：1999-03-02
申请号：US833962
申请日：1997-04-11
申请人： Per Lindberg , Lars Weidolf
发明人： Per Lindberg , Lars Weidolf
IPC分类号： C07D401/12 , A61K31/44
CPC分类号： C07D401/12 , Y10S514/819 , Y10S514/927
摘要： A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-��(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H-benzimidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.
摘要翻译：通过抑制胃酸分泌来治疗胃酸相关疾病的方法，包括向需要治疗的哺乳动物施用治疗有效量的5-甲氧基-2 - [[（4-甲氧基-3 ，5-二甲基-2-吡啶基）甲基]亚磺酰基] -1 + E，非H + EE-苯并咪唑或其药学上可接受的盐，以便在施用时降低血浆水平的个体间变化。还要求使用奥美拉唑的（ - ） - 对映异构体，与外消旋奥美拉唑相比，施用相同剂量的奥美拉唑（ - ） - 对映异构体时，平均血浆水平升高（AUC）抗分泌作用和更好的临床疗效。

4. 发明申请

US20130214515A1 BRACKET FOR FASTENING OF A CURTAIN AIRBAG TO A VEHICLE PART 有权
标题翻译：用于将窗帘安装到车辆部分的支架
公开(公告)号：US20130214515A1
公开(公告)日：2013-08-22
申请号：US13879428
申请日：2011-09-05
申请人： Jonas Malmenstam , Per Lindberg , Hakan Jaconelli , Atsushi Nakshima , Tetsuya Matshushita
发明人： Jonas Malmenstam , Per Lindberg , Hakan Jaconelli , Atsushi Nakshima , Tetsuya Matshushita
IPC分类号： B60R21/20
CPC分类号： B60R21/20 , B60R21/213 , B60R21/232 , B60R21/2338 , B60R2021/23386
摘要： A bracket for fastening a tightening strap of a curtain airbag to a vehicle part includes a base plate and a support surface for fastening the bracket to the vehicle part. A retaining web, fastenable to the tightening strap, is located on the bracket in such a way that the retaining web can be moved to a fastening position by performing a swivel motion with the bracket being supported on the vehicle part via the support surface.
摘要翻译：用于将帘式气囊的紧固带紧固到车辆部件的支架包括基板和用于将支架紧固到车辆部件的支撑表面。可固定在紧固带上的保持网以这样一种方式位于支架上，使得保持腹板可以通过经由支撑表面支撑在车辆部件上的支架执行旋转运动而移动到紧固位置。

5. 发明申请

US20090197919A1 Novel Method for Preparation of Ammonium Salts of Esomeprazole 审中-公开
标题翻译：新型艾美拉唑铵盐的制备方法
公开(公告)号：US20090197919A1
公开(公告)日：2009-08-06
申请号：US12303332
申请日：2007-06-07
申请人： Rolf Bergman , Christina Fregler , Per Lindberg
发明人： Rolf Bergman , Christina Fregler , Per Lindberg
IPC分类号： A61K31/4439 , C07D401/12
CPC分类号： C07D401/12
摘要： The present invention relates to a process for the preparation of quartenary ammoniumsalts of esomeprazole. Further, the present invention also relates to the use quartenary ammoniumsalts of esomeprazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as the quartenary ammoniumsalts of esomeprazole, as such.
摘要翻译：本发明涉及一种制备埃索美拉唑的季铵盐铵盐的方法。此外，本发明还涉及用于治疗胃肠道疾病的埃索美拉唑的季铵盐酸铵，含有它们的药物组合物以及埃索美拉唑的季铵盐铵盐。

6. 发明授权

US5776765A Method for preparing a pharmaceutically active enantiomeric or enantiomerically enriched sulfoxide compound by enantioselective bioreduction of a racemate sulfoxide compound 失效
标题翻译：通过外消旋亚砜化合物的对映选择性生物还原来制备药物活性对映体或对映异构体富集的亚砜化合物的方法
公开(公告)号：US5776765A
公开(公告)日：1998-07-07
申请号：US569083
申请日：1995-12-18
申请人： Daniel Graham , Robert Holt , Per Lindberg , Stephen Taylor
发明人： Daniel Graham , Robert Holt , Per Lindberg , Stephen Taylor
IPC分类号： C12P41/00 , A61K31/44 , A61K31/4427 , A61P1/04 , C07D401/12 , C12P17/18 , C12R1/19 , C12R1/37 , C12P11/00
CPC分类号： C07D401/12 , C12P17/182 , C12P17/185 , Y10S435/822 , Y10S435/849 , Y10S435/873
摘要： A compound of formula (II), either as a single enantiomer or in an enantiomerically enriched form ##STR1## wherein: ##STR2## and ##STR3## (wherein N in the benzimidazole moiety of Het.sub.2 means that one of the carbon atoms substituted by any one of R.sub.6 to R.sub.9 optionally may be exchanged for an unsubstituted nitrogen atom; R.sub.1, R.sub.2 and R.sub.3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl, phenylakoxy; R.sub.4 and R.sub.4, are the same or different and selected from hydrogen, alkyl, aralkyl; R.sub.5 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy; R.sub.6 -R.sub.9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl or adjacent groups R.sub.6 -R.sub.9 may complete together with the carbon atoms to which they are attached optionally substituted ring structures; R.sub.10 is hydrogen or alkoxycarbonyloxymethyl; R.sub.11 is hydrogen or forms an alkylene chain together with R.sub.3 ; R.sub.12 and R.sub.13 are the same or different and selected from hydrogen, halogen or alkyl) is obtained by stereoselective bioreduction of a compound of formula (II) in racemic form.
摘要翻译： PCT No.PCT / SE95 / 01416 Sec。 371 1995年12月18日第 102（e）1995年12月18日PCT PCT 1995年11月27日提交的式（II）化合物作为单一对映异构体或以对映异构体富集形式（II），其中：＆lt; IMAGE＆gt;和＆lt; IMAGE＆（其中Het2的苯并咪唑部分中的N表示被R6至R9中任一个取代的碳原子之一任选地可以被替换为未取代的氮原子; R 1，R 2和R 3相同或不同，并且选自氢，烷基，任选被氟取代的烷氧基，烷硫基，烷氧基烷氧基，二烷基氨基，哌啶子基，吗啉代，卤素，苯基烷基，苯基烷氧基; R4和R4相同或不同，选自氢，烷基，芳烷基; R5是氢，三氟甲基，烷基，烷氧基; R6 -R9相同或不同，选自氢，烷基，烷氧基，卤素，卤代烷氧基，烷基羰基，烷氧基羰基，恶唑基，三氟烷基或相邻基团R6 -R9可以与它们任选地替换环形结构; R 10是氢或烷氧基羰氧基甲基; R 11是氢或与R 3一起形成亚烷基链; R 12和R 13相同或不同，选自氢，卤素或烷基）通过外消旋形式的式（II）化合物的立体选择性生物还原获得。

7. 发明申请

US20060004057A1 New compounds 审中-公开
标题翻译：新化合物
公开(公告)号：US20060004057A1
公开(公告)日：2006-01-05
申请号：US11002982
申请日：2004-12-01
申请人： Per Lindberg , Sverker Von Unge
发明人： Per Lindberg , Sverker Von Unge
IPC分类号： A61K31/4439 , C07D43/02
CPC分类号： C07D401/12
摘要： The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
摘要翻译：新型光学纯化合物Na +，Mg 2+，Li +，K +，SO 2 + （+） - 5-甲氧基-2 - [[（4-甲氧基-3,5-二氢 - 噻吩-2-基）（ - ） - 5-甲氧基-2 - [[（4-甲氧基-3,5-二甲基-2-吡啶基）甲基]亚磺酰基] ）甲基]亚磺酰基] -1

8. 发明授权

US06599927B2 Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome 失效
标题翻译：使用H +，K + -ATPase抑制剂治疗Widal综合征
公开(公告)号：US06599927B2
公开(公告)日：2003-07-29
申请号：US09833599
申请日：2001-04-13
申请人： Per Lindberg , Joan Piñas-Massó , Jordi Serra-Carreras , Jan Trofast
发明人： Per Lindberg , Joan Piñas-Massó , Jordi Serra-Carreras , Jan Trofast
IPC分类号： A61K31415
CPC分类号： A61K31/435 , A61K9/0014 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , A61K31/57 , A61K2300/00
摘要： The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
摘要翻译：本发明提供一种治疗息肉病的方法，其包括用H +，K + -ATP酶抑制剂和任选的糖皮质激素治疗患有息肉病的受试者。本发明还涉及用于在治疗Widal氏综合征和哮喘治疗中同时，分别或连续给药的药物制剂。

9. 发明授权

US06380222B2 Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps 失效
标题翻译：使用H +，K + -ATPase抑制剂治疗鼻息肉
公开(公告)号：US06380222B2
公开(公告)日：2002-04-30
申请号：US09833699
申请日：2001-04-13
申请人： Per Lindberg , Joan Piñas-Massó , Jordi Serra-Carreras , Jan Trofast
发明人： Per Lindberg , Joan Piñas-Massó , Jordi Serra-Carreras , Jan Trofast
IPC分类号： A61K3141
CPC分类号： A61K31/435 , A61K9/0014 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , A61K31/57 , A61K2300/00
摘要： The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+,K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
摘要翻译：本发明提供一种治疗息肉病的方法，其包括用H +，K + -ATP酶抑制剂和任选的糖皮质激素治疗患有息肉病的受试者。本发明还涉及用于在治疗Widal氏综合征和哮喘治疗中同时，分别或连续给药的药物制剂。

10. 发明授权

US5840552A Preparation of pharmaceutically active compounds by biooxidation 失效
标题翻译：通过生物氧化制备药物活性化合物
公开(公告)号：US5840552A
公开(公告)日：1998-11-24
申请号：US569114
申请日：1996-11-21
申请人： Robert Holt , Per Lindberg , Christopher Reeve , Stephen Taylor
发明人： Robert Holt , Per Lindberg , Christopher Reeve , Stephen Taylor
IPC分类号： C12P41/00 , A61K31/44 , A61K31/4427 , A61P1/04 , C07D401/12 , C12P17/10 , C12P17/18 , C12R1/06 , C12R1/13 , C12R1/32 , C12R1/645 , C12R1/685 , C12R1/80 , C12P17/16
CPC分类号： C07D401/12 , C12P17/10 , C12P17/185
摘要： Enantiomeric or enantiomerically enriched H.sup.+ K.sup.+ ATPase inhibiting pyridinylsulfinyl--benzimidazoles are prepared using microorganisms or microbial enzyme systems to enantioselectively biooxidize corresponding prochiral sulfide compounds and isolating the pharmaceutically active enantiomer or enantiomerically enriched sulfoxide form.
摘要翻译： PCT No.PCT / SE95 / 01415 Sec。 371日期：1996年11月21日 102（e）日期1996年11月21日PCT 1995年11月27日PCT公布。公开号WO96 / 17076 日期1996年6月6日使用微生物或微生物酶系统制备对映体或对映异构体富集的H + K + ATP酶抑制吡啶基亚磺酰基 - 苯并咪唑，以对映选择性地生物氧化相应的前手性硫化物化合物并分离药物活性对映体或对映体富集的亚砜形式。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式